FOMX Swing Trade IdeaLooking slowly and slowly ready to move up. Will look to swing up to $3.30 - $4.00 over the next 30/60 days.
Similar setup to last run and today's hammer makes me have hope. Small play but market appears to be calm these days.
GLTA
FOMX
FOMX - Foamix Pharma Reversal Pattern FormedOn October 18th, 2019, the FDA approved Amzeeq, otherwise known as FMX101 for the Israel based pharmaceutical company, Foamix. Amzeeq happens to be the first and only topical monocyline treatment to be used on acne patients. In anticipation of approval for this new product, shares of FOMX rallied from $2.53 per share on 10/08/2019 all the way up to highs around $3.63 per share. As it turns out, the anticipation for the approval is now correcting lower to what seemed to be overbought conditions in anticipation. FOMX 101 is expected to be entering into the market early next year with the hopes of being on shelves for January 2020. This new topical treatment will be entering the dermatology market which happens to be worth several billion dollars. This is very good news for a company that has been anticipating FDA approval for several years, these are make or break moments for new companies.
If you look at the chart above, I posted what seems to be a hammer which I am waiting for the end of the day for confirmation. If this pattern holds, this may be a reversal pattern to hop into FOMX to join the reversal towards December price targets between $3-$6 dollars. Watch to see if the hammer pattern holds, then watch to see if the reversal in confirmed. If we see a reversal, we may be looking towards short terms gains of 25% and higher. Option markets are pricing in a high volume of $4 and $5 strike price calls for december.
Cheers,
AC
FOMX - Momentum Still Going - Can We Hit The 3rd Target!Foamix Pharmaceuticals Ltd. is a pharmaceutical company, which focuses on the development and commercialization of proprietary, innovative and differentiated topical drugs for dermatological therapy. Its product portfolios include minocycline foam, minocycline gel, mometasone foam, calcipotriene foam, triamcinolone acetonide foam, betamethasone valerate foam, and betamethasone dipropionate. The company was founded by Dov Tamarkin and Meir Eini on January 19, 2003 and is headquartered in Rehovot, Israel.
P/E Current
-1.64
P/E Ratio (with extraordinary items)
-2.3
SHORT INTEREST
2.33M 07/31/19
Average Recommendation: BUY
Average Target Price: 15.60
FOMX - Bulls Arrive As Big Investment HappensFoamix Pharmaceuticals Ltd. is a clinical-stage pharmaceutical company. The Company is engaged in the development and commercialization of foam-based formulations, using its technology, which includes its foam platforms. It is focused on developing and commercializing its minocycline foam for the treatment of acne, rosacea and other skin conditions. Its product candidates include FMX101, FMX102, FMX103 and FDX104. Its lead product candidate, FMX101, is a topical foam formulation of the antibiotic minocycline for the treatment of moderate-to-severe acne. FMX102 is a formulation of its minocycline foam being developed for the treatment of impetigo. FMX103 is a topical foam formulation of minocycline for the treatment of moderate-to-severe Papulopustular rosacea. FDX104 is a topical foam formulation of the antibiotic doxycycline for the treatment of severe acne-like rashes induced by chemotherapy. It has conducted one Phase II clinical trial for each of FMX101, FMX102, FMX103 and FDX104.
Foamix Pharmaceuticals Ltd. (FOMX), (“Foamix”), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical therapies to address unmet needs in dermatology, today announced that it has secured up to $64 million in financing from Perceptive Advisors and OrbiMed. The financing consists of term loans of up to $50 million under a Credit Agreement, with $15 million provided immediately upon satisfaction of certain closing conditions, $20 million available upon the achievement of certain regulatory milestones and $15 million available upon the achievement of certain revenue milestones. Additionally, the Company will receive $14 million in gross proceeds from Perceptive Advisors through a direct registered offering of the Company’s ordinary shares. Proceeds from the transactions are expected to be used to fund the Company’s filing of a New Drug Application (“NDA”) with the FDA for FMX103 for the treatment of papulopustular rosacea as well as, assuming FDA approval is received, the anticipated product launches of FMX101 for the treatment of moderate to severe acne and FMX103, as well as for working capital and general corporate purposes. The FDA has established October 20th, 2019 as the Prescription Drug User Fee Act (PDUFA) action date for FMX101, and Foamix is in the final stages of preparation for the NDA submission for FMX103. (Source finance.yahoo.com)
SHORT INTEREST
2.11M 07/15/19
Average Recommendation: BUY
Average Target Price: 15.60
P/E Current
-1.26
P/E Ratio (with extraordinary items)
-1.84
FOMX - Fallen angel type Long from $4.47 to $5.33FOMX had huge decline & now it is forming up a nice fallen angel bottom. If it can break above its SMA20 it can fill the gap up to $5.33 easily.
* Trade Criteria *
Date First Found- May 1st, 2017
Pattern/Why- Fallen angel
Entry Target Criteria- Break of $4.47
Exit Target Criteria- $5.33
Stop Loss Criteria- $4.07
Please check back for Trade updates. (Note: Trade update is little delayed here.)
USDCAD Hello everyone, we have an opportunity to short this pair and I have highlighted the targets on the chart.
For any questions leave a comment or DM me.
Good Luck
SELL NZDUSD @0.73 - TP 700PIPS: BREXIT, RBNZ, FED & USDJPY HEDGEShort NZDUSD is in my top 2 FX Trades for several reasons:
1. NZD is considered the riskiest G10 currency cross, so NZD trades weaker in risk-off markets, or when equities/ SPX trade lower (you can see the high correlation with SPX at the bottom of the graph).
- With Brexit occurring last week, global risk has increased, this is especially the case for NZD due to commonwealth connections. Therefore NZD is likely to come under pressure in the future as risk-off sentiment continues to dominate, as the US Election nears, Global growth worries continue (Japan, Europe, China) and Brexit/ uncertainty about further EuroArea exits continues to intensify - we can see Gold and US Treasuries continue to gain supporting the risk-off view and thus supporting selling NZD. Also, risk-off encourages $ buying as a safe haven deposit on the Brexit backdrop.
- Further, going into earnings season next week, historically risk currencies (NZD) perform poorly as investors seek safer assets to hedge against earning surprises, thus this helps NZD selling and USD buying. Plus, most investors will want to hold some $ cash in order to fulfil their earnings based equity trading, so this also helps the short Kiwi$ trade by increasing $ demand relative to NZD.
2. The RBNZ Meeting on the 10th August is likely to be dovish and I 80% expect a rate cut of 25-50bps from 2.25% to 2.00%-1.75% , as;1) Brexit risks are weighed in on and potentially priced into a rate decision, in follow up to the supportive/ dovish statements from RBNZ members immediately after the Brexit decision and 2) NZD Macro Environment has performed poorly since the March Rate cut from 2.5% to 2.25% e.g. The last prints still consistently dragging: Retail Sales at 1.0% vs 1.1%qoq & 0.8% vs 1% Q1qoq; CPI 0.4% yoy, 0.2% qoq; Unemployment Rate at 5.7% vs 5.5%. 3) the RBNZ has a historical pattern of cutting their rate every third meeting, and this August meeting is the third meeting. Plus it will have been 5 months since their last cut in March - this also historically is a large time for a another rate cut as previously to that the RBNZ cut in December, Dec-Mar which was only 3 months, and before that in october (oct-dec) which was 2 months so the odds are good if NZD data continues to be bad given the time since the last cut of 5 months is relatively large. And the gap since their last meeting at June 10th is 2 months which is the biggest gap they have.
- Risks to the RBNZ Rate cut view are that;1) Brexit risks are de-priced due to UK Political skulduggery pushing the likelihood of the brexit into 2017 (if at all) 2) Their Inflation, Employment and GDP data manage to recover and show structural signs that the rate at 2.25% is sufficient for continued economic recovery e.g. NZD May Employment Change print surprised to the upside at 1.2% vs 0.8%, and their June GDP outperformed for Q1 at 0.7% vs 0.5% qoq & 2.8% vs 2.6% yoy. So if the CPI and employment data due to be released before the RBNZ August 10th meeting shows a continued/ structural/ aggressive recovery this will reduce the likelihood of a rate cut. Nonetheless, my money is that this isn't the case (with data continuing to trade subdued) and I therefore expect them to provide reassurance to markets with a strong dovish tone, and a 25bps cut - citing Brexit and non-outstanding economic indicators as the impetus for the changed policy.
*It should be noted, in order for me NOT to consider a 25bps cut likely in August we would have to see an outstanding CPI and employment print e.g. CPI 1.0%-0.8% (0.4% last), and unemployment 5.3/4% (5.7% last), given it has been 5 months since the last cut - the RBNZ would be expecting to see such figures to consider the current rate of 2.25% as working/ sufficient.
